GTC Biotherapeutics gets $1 million milestone payment from LEO Pharma

By Elaine Rigoli

Tampa, Fla., June 14 - GTC Biotherapeutics, Inc. has received a $1 million payment from LEO Pharma A/S for achieving the milestone of a positive opinion on the market authorization application for ATryn from the Committee for Medicinal Products for Human Use of the European Medicines Agency.

The committee has recommended that ATryn, GTC's recombinant form of human antithrombin, be granted market authorization for the prophylaxis of venous thromboembolism in surgery of patients with congenital antithrombin deficiency.

Final market authorization by the European Commission, which is expected in about three months, will trigger an additional $2 million milestone payment from LEO Pharma, according to a news release.

In November 2005, GTC and LEO Pharma entered into a collaboration to develop and market ATryn in Europe, Canada and the Middle East.

GTC Biotherapeutics is a Framingham, Mass.-based developer of therapeutic proteins through transgenic animal technology.

© 2015 Prospect News.
All content on this website is protected by copyright law in the U.S. and elsewhere. For the use of the person downloading only.
Redistribution and copying are prohibited by law without written permission in advance from Prospect News.
Redistribution or copying includes e-mailing, printing multiple copies or any other form of reproduction.